Through our established model of HRS-induced myositis that has allowed us to explore immunopathogenic mechanisms of the anti-synthetase syndrome, we have demonstrated that mice immunized with recombinant HRS develop antibodies against additional autoantigens including both Ro52 and Ro60. This evidence concerns the gene TRIM21 and myositis disease.